全文获取类型
收费全文 | 17108篇 |
免费 | 1140篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 349篇 |
儿科学 | 436篇 |
妇产科学 | 474篇 |
基础医学 | 2500篇 |
口腔科学 | 301篇 |
临床医学 | 1495篇 |
内科学 | 2872篇 |
皮肤病学 | 647篇 |
神经病学 | 1955篇 |
特种医学 | 880篇 |
外科学 | 2761篇 |
综合类 | 144篇 |
一般理论 | 21篇 |
预防医学 | 986篇 |
眼科学 | 440篇 |
药学 | 887篇 |
中国医学 | 11篇 |
肿瘤学 | 1121篇 |
出版年
2022年 | 138篇 |
2021年 | 251篇 |
2020年 | 166篇 |
2019年 | 270篇 |
2018年 | 331篇 |
2017年 | 275篇 |
2016年 | 353篇 |
2015年 | 355篇 |
2014年 | 528篇 |
2013年 | 606篇 |
2012年 | 896篇 |
2011年 | 942篇 |
2010年 | 553篇 |
2009年 | 531篇 |
2008年 | 773篇 |
2007年 | 859篇 |
2006年 | 800篇 |
2005年 | 771篇 |
2004年 | 697篇 |
2003年 | 673篇 |
2002年 | 664篇 |
2001年 | 520篇 |
2000年 | 521篇 |
1999年 | 478篇 |
1998年 | 207篇 |
1997年 | 202篇 |
1996年 | 171篇 |
1995年 | 156篇 |
1994年 | 147篇 |
1993年 | 117篇 |
1992年 | 331篇 |
1991年 | 321篇 |
1990年 | 271篇 |
1989年 | 290篇 |
1988年 | 239篇 |
1987年 | 224篇 |
1986年 | 252篇 |
1985年 | 226篇 |
1984年 | 167篇 |
1983年 | 135篇 |
1982年 | 85篇 |
1981年 | 91篇 |
1979年 | 125篇 |
1978年 | 98篇 |
1977年 | 83篇 |
1975年 | 85篇 |
1974年 | 101篇 |
1973年 | 108篇 |
1971年 | 95篇 |
1970年 | 84篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
42.
A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. 总被引:3,自引:0,他引:3
Pavel Sova Xiao-Wei Ren Shaoheng Ni Kathrin M Bernt Jie Mi Nancy Kiviat André Lieber 《Molecular therapy》2004,9(4):496-509
We have constructed a new capsid-modified adenovirus (Ad) vector that specifically replicates in tumor cells and expresses TNF-related apoptosis-inducing ligand (TRAIL). The Ad capsid contains short-shafted fibers derived from Ad serotype 35, which allow for efficient infection of malignant tumor cells, and largely avoids innate toxicity after intravenous application. Replication-dependent homologous recombination in Ad genomes was used to achieve tumor-specific expression of Ad E1a (to mediate viral replication) and TRAIL (to mediate apoptosis and enhance release of progeny virus from infected cells). We demonstrated that our oncolytic vector (Ad5/35.IR-E1A/TRAIL) induced apoptosis in human tumor cell lines derived from colorectal, lung, prostate, and liver cancer. Both in vitro and in vivo tumor models showed efficient intratumoral spread of this vector. In a model for metastatic colon cancer, tail vein infusion of Ad5/35.IR-E1A/TRAIL resulted in elimination of preestablished liver metastases. Intravenous injection of this vector caused a transient elevation of serum glutamic pyruvic transaminase in tumor-bearing mice, which we attributed to factors released from apoptotic tumor cells. Liver histology analyzed at day 14 after virus injection did not show signs of hepatocellular damage. This new oncolytic vector represents a potentially efficient means for gene therapy of metastatic cancer. 相似文献
43.
44.
45.
Combination of intermittent haemodialysis and high-volume continuous haemofiltration for the treatment of severe metformin-induced lactic acidosis. 总被引:15,自引:2,他引:13
Ulf Panzer Stefan Kluge Georg Kreymann Gunter Wolf 《Nephrology, dialysis, transplantation》2004,19(8):2157-2158
Sir, Metformin has been used for many decades as an effective glucose-loweringmedication in the treatment of type 2 diabetes mellitus. Recentstudies clearly demonstrated that metformin reduced secondarycomplications of diabetes mellitus type 2 without promotingweight gain, which is in contrast to treatment with insulinand/or sulphonylurea [1]. Lactic acidosis is a serious sideeffect observed with metformin treatment and 相似文献
46.
D. M. Wolf R. Rokicka-Milewska† S. Lopaciuk† A. B. Skotnicki§ A. Klukowska† P. Laguna† J. Windyga‡ R. Kotitschke W. G. Struff 《Haemophilia》2004,10(5):438-448
Clinical efficacy, safety and pharmacokinetic properties of the high-purity double-virus inactivated plasma-derived factor VIII concentrate Haemoctin SDH (pdFVIII) were evaluated in three prospective open-label uncontrolled studies in previously treated patients (PTPs) with severe haemophilia A. The pharmacokinetic properties assessed at baseline and after 3 months of treatment are in accurate accordance with published data and remain unchanged over time (study A, n = 12). Mean terminal elimination half-life was 11.8 and 11.9 h, mean incremental recovery (IU dL(-1)/IU kg(-1)) was 2.3 and 2.0, respectively. Long-term efficacy and safety, in particular the potential immunogenicity, were investigated in a total of 53 PTPs (studies A and B) treated prophylactically and on-demand, as required. PdFVIII has shown to be effective in preventing and controlling bleeding episodes; 23.5% of patients were free of bleeding events. A total of 177 haemorrhages occurred with 74.0% resolving after a single infusion, 87.6% within two infusions. 98.3% of responses reported on haemorrhages were rated as 'excellent' or 'good'. Moreover, 'excellent' haemostatic efficacy has been demonstrated in 10 surgical procedures including general and severe orthopaedic interventions (study C). No complication occurred in any surgery. Few adverse events were reported, one patient developed a high-titre FVIII inhibitor without clinical relevance. In all three studies, over 6 million units were administered in nearly 4300 infusions, approximately 94% units or infusions were given for prophylaxis and only 6% for treatment on-demand. In conclusion, pdFVIII has shown to be effective, safe and well tolerated in long-term prophylaxis and treatment on-demand as well as after minor and major surgical procedures. 相似文献
47.
48.
49.
Application of urologic techniques to nonurinary calculi 总被引:1,自引:0,他引:1
50.